ÂÜŔňÂŇÂ×

Wildon brings expertise in clinical development and medical affairs in neuromuscular diseases and oligonucleotide therapies. He joined Dyne from Biogen, Inc., where he was vice president, and global head of neuromuscular diseases, and medical affairs. During his 10 years at Biogen, Wildon led the development and life cycle management of SPINRAZA® (nusinersen), an oligonucleotide and the first therapy approved for the treatment of spinal muscular atrophy. He also led the late-stage development of tofersen, an investigational oligonucleotide therapy for amyotrophic lateral sclerosis, oversaw clinical and biomarker development for Biogen’s neuromuscular disease portfolio and began his tenure at the company leading pharmacovigilance for multiple product candidates. Previously, Wildon was an Assistant Professor in Medicine at Harvard Medical School and a physician at Brigham and Women’s Hospital and the VA Boston Healthcare System. He received his M.D. from the University of Missouri School of Medicine and an MPH in clinical effectiveness from Harvard University School of Public Health.